Azirkitug Clinical Trials (2026): 1 Studies for Gastric/Esophageal Cancer & Head and Neck Squamous Cell Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Azirkitug clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Gastric/Esophageal Cancer & Head and Neck Squamous Cell Carcinoma) and 694 total planned enrollment. 1 Azirkitug clinical trial is actively recruiting at 19 U.S. sites across 11 states. Most recent activity: NCT05005403 (Jul 2027).
Where to Participate: All Azirkitug Trial Sites in the U.S. (19 sites across 11 states)
Every actively recruiting Azirkitugtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope National Medical Center /ID# 276272 | Duarte91010 | NCT05005403 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589 | Irvine92618 | NCT05005403 | Map |
| CA | USC Norris Comprehensive Cancer Center /ID# 279603 | Los Angeles90033 | NCT05005403 | Map |
| IL | University of Illinois Hospital and Health Sciences System /ID# 251750 | Chicago60607 | NCT05005403 | Map |
| IN | Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593 | Fort Wayne46804 | NCT05005403 | Map |
| IN | Community Health Network, Inc. /ID# 243011 | Indianapolis46250-2042 | NCT05005403 | Map |
| KY | Norton Cancer Institute /ID# 248903 | Louisville40241-2832 | NCT05005403 | Map |
| MI | START Midwest /ID# 248685 | Grand Rapids49546-7062 | NCT05005403 | Map |
| MN | M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200 | Minneapolis55455 | NCT05005403 | Map |
| NE | Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399 | Omaha68130 | NCT05005403 | Map |
| NC | Duke Cancer Institute /ID# 276267 | Durham27710 | NCT05005403 | Map |
| NC | Carolina BioOncology Institute /ID# 232597 | Huntersville28078 | NCT05005403 | Map |
| TX | NEXT Oncology Austin /ID# 243005 | Austin78705-1171 | NCT05005403 | Map |
| TX | The University of Texas MD Anderson Cancer Center /ID# 270059 | Houston77030 | NCT05005403 | Map |
| TX | Next Oncology Dallas /ID# 276254 | Irving75039 | NCT05005403 | Map |
| TX | NEXT Oncology /ID# 243007 | San Antonio78229 | NCT05005403 | Map |
| TX | South Texas Accelerated Research Therapeutics (START) /ID# 276268 | San Antonio78229 | NCT05005403 | Map |
| UT | Start Mountain Region /ID# 276270 | West Valley City84119 | NCT05005403 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 232592 | Fairfax22031 | NCT05005403 | Map |
Azirkitug clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting Azirkitug clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05005403 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | P1 | Non-Small Cell Lung Cancer | 694 | Nov 2021 |
All Azirkitug trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05005403 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | P1 | recruiting | 694 | AbbVie | Nov 2021 |
Azirkitug clinical trials: frequently asked questions
- How many Azirkitug clinical trials are there?
- 1 Azirkitug clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Azirkitug clinical trials recruiting in 2026?
- Yes — 1 Azirkitug trial is actively recruiting in 2026, with 19 U.S. sites across 11 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Azirkitug being studied for?
- Azirkitug is being studied for Gastric/Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, High-Grade Serous Ovarian Cancer, Micro Satellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer and 2 more. The trials are grouped by indication on this page.
- What phase is Azirkitug in?
- Azirkitug clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Azirkitug clinical trials?
- The lead sponsor across the most Azirkitug trials is AbbVie. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Azirkitugas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: